Streetbeat News

Earnings

ARMH

Arm Holdings reported its Q2 financial results and issued guidance, which led to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:19 pm

CMRA

Comera Life Sciences (NASDAQ:CMRA) reported Q3 losses of $(0.10) per share, a 50% improvement from $(0.20) per share YoY. However, sales decreased by 41.98% to $136.31K from $234.92K YoY.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:19 pm

SANW

S&W Seed (NASDAQ:SANW) reported Q1 adjusted losses of $(0.11) per share, missing the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease from the same period last year. The company also reported quarterly sales of $16.43 million, missing the analyst consensus estimate of $18.00 million by 8.71 percent, a 17.29 percent decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:18 pm

VERA

Vera Therapeutics reported Q3 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.54) by 16.67%. This represents a 50.55% increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:18 pm

AMTX

Aemetis reported Q3 sales of $68.69M, missing the analyst consensus estimate of $75.50M by 9.02%. This is a 4.37% decrease from the same period last year. However, the company's gross profit was $492,000, compared to a $1.1M gross loss in the year-ago period. The India Biodiesel segment provided $2.8M in gross income.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:18 pm

AMTX

Aemetis (NASDAQ:AMTX) reported Q3 earnings of $0.73 per share, beating the analyst consensus estimate of $(0.29) by 351.72 percent. However, the company's quarterly sales of $68.69 million missed the analyst consensus estimate of $75.50 million by 9.02 percent.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:17 pm

CADL

Candel Therapeutics reported Q3 losses of $(0.29) per share, missing the analyst consensus estimate of $(0.19) by 52.63 percent. However, this is a 3.33 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:15 pm

RLYB

Rallybio (NASDAQ:RLYB) reported its Q3 earnings, beating estimated earnings by 11.76% with an EPS of $-0.45 versus an estimate of $-0.51. However, revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.02, which was followed by a 0.38% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 1:15 pm

ACRV

Acrivon Therapeutics (NASDAQ:ACRV) reported its Q3 earnings, beating estimated earnings by 7.04% with an EPS of $-0.66 versus an estimate of $-0.71. However, revenue was down $0 from the same period last year. Last quarter, the company beat EPS by $0.02, which led to a 6.81% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 1:15 pm

PHAT

Phathom Pharmaceuticals reported Q3 losses of $(0.76) per share, beating the analyst consensus estimate of $(0.89) by 14.61%. This is a 42.42% increase over losses of $(1.32) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:14 pm